Literature DB >> 8932886

The course of schizophrenia over 13 years. A report from the International Study on Schizophrenia (ISoS) coordinated by the World Health Organization.

P Mason1, G Harrison, C Glazebrook, I Medley, T Croudace.   

Abstract

BACKGROUND: This paper describes the 13 year course of illness in an epidemiologically defined and representative cohort of patients selected when they were experiencing their first episode of schizophrenia.
METHOD: In a 13-year follow-up study of 67 patients with ICD-9 schizophrenia, identified in Nottingham in 1978-80, the course of illness (symptoms, disability and hospitalisation) was assessed using standardised instruments, applied at onset, 1,2, and 13 years. Time to first relapse and first readmission were calculated and plotted as survival curves and patients were assigned to the course types described by Ciompi.
RESULTS: The survival curves show that first relapses and first readmissions occur during the first five years. The amount of time spent in psychotic episodes and in hospital is greatest in the first year of follow-up, but stable thereafter. Social adjustment improves from entry to the study to the first follow-up year, but there is a small deterioration in social adjustment between 2 and 13 years.
CONCLUSIONS: The findings reported suggest that after the initial episode the course of schizophrenia is relatively stable. The data support neither concepts of progressive deterioration nor progressive amelioration. There was no evidence of a "late recovery'.

Entities:  

Mesh:

Year:  1996        PMID: 8932886     DOI: 10.1192/bjp.169.5.580

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  11 in total

1.  The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study.

Authors:  Paul E Bebbington; Matthias Angermeyer; Jean-Michel Azorin; Traolach Brugha; Reinhold Kilian; Sonia Johnson; Mondher Toumi; Asa Kornfeld
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-09       Impact factor: 4.328

Review 2.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

Review 3.  Is active psychosis neurotoxic?

Authors:  T H McGlashan
Journal:  Schizophr Bull       Date:  2006-08-16       Impact factor: 9.306

Review 4.  Diagnosis of schizophrenia: consistency across information sources and stability of the condition.

Authors:  Philip D Harvey; Robert K Heaton; William T Carpenter; Michael F Green; James M Gold; Michael Schoenbaum
Journal:  Schizophr Res       Date:  2012-04-13       Impact factor: 4.939

Review 5.  Compliance therapy for schizophrenia.

Authors:  A M McIntosh; L Conlon; S M Lawrie; A C Stanfield
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

6.  Multifamily psychoeducation for first-episode psychosis: a cost-effectiveness analysis.

Authors:  Nicholas J K Breitborde; Scott W Woods; Vinod H Srihari
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

7.  Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care.

Authors:  Raphael J. Leo; Paula Del Regno
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-12

8.  Early intervention in schizophrenia.

Authors:  Parmanand Kulhara; Anindya Banerjee; Alakananda Dutt
Journal:  Indian J Psychiatry       Date:  2008-04       Impact factor: 1.759

9.  Schizophrenia in real life: courses, symptoms and functioning in an Italian population.

Authors:  Maria Cristina Turola; Gloria Comellini; Anna Galuppi; Maria Giulia Nanni; Emanuela Carantoni; Chiara Scapoli
Journal:  Int J Ment Health Syst       Date:  2012-10-09

10.  A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.

Authors:  Maarten Treur; Bart Heeg; Hans-Jürgen Möller; Annette Schmeding; Ben van Hout
Journal:  BMC Health Serv Res       Date:  2009-02-18       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.